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Background: Adverse transfusion reactions (ATRs) are clinically relevant to patients with 
significant morbidity and mortality. This study aimed to review the cases of ATR reported 
in the recipient-triggered trace back system for a recent nine-year period in Korea.
Methods: Nine-year data obtained from 2006 to 2014 by the trace back system at the Di-
vision of Human Blood Safety Surveillance of the Korean Centers for Disease Control 
(KCDC) were reviewed. The suspected cases were assessed according to six categories: (i) 
related to, (ii) probably related to, (iii) probably not related to, (iv) not related to transfu-
sion, (v) unable to investigate, and (vi) under investigation. 
Results: Since 2006, 199 suspected serious ATRs were reported in hospitals and medical 
institutions in Korea, and these ATRs were reassessed by the division of Human Blood 
Safety Surveillance of the KCDC. Among the reported 193 cases as transfusion related in-
fections, hepatitis C virus (HCV) infection (135, 67.8%) was reported most frequently, fol-
lowed by hepatitis B virus (HBV) infection (27, 13.6%), HIV infection (13, 6.5%), syphilis 
(9, 4.5%), malarial infection (4, 2.0%), other bacterial infections (3, 1.5%), HTLV infection 
(1, 0.5%), and scrub typhus infection (1, 0.5%), respectively. Of the 199 cases, 13 (6.5%) 
cases were confirmed as transfusion-related (3 HCV infections, 3 malarial infections, 1 
HBV infection, 2 Staphylococcus aureus sepsis, 3 transfusion-related acute lung injuries, 
and 1 hemolytic transfusion reaction). 
Conclusions: This is the first nationwide data regarding serious ATRs in Korea and could 
contribute to the implementation of an effective hemovigilance system.
Key Words: Adverse transfusion reactions, Trace back system, Korea, Hemovigilance sys-
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INTRODUCTION
The national blood program was consigned to the Korean Red 
Cross (KRC) in 1981, but the emergence of six cases of transfu-
sion-induced AIDS in 2004 instigated safety concerns from the 
public, and this led to strengthening the supervision of the na-
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tional blood business to ensure blood safety [1]. The Korean 
blood transfusion community announced that they would initi-
ate actions to further improve safety measures since September 
2004, and the Korean Hemovigilance System has been started 
[2].There is no doubt that hemovigilance will continue to help 
improve the quality and safety of blood transfusions. Therefore, 
in many countries, hemovigilance networks have been intro-
duced for monitoring adverse transfusion reactions (ATRs) and 
restructured according to the different health systems of the in-
dividual countries [3-6]. Depending on social security and na-
tional priorities, various hemovigilance models have been used 
[7, 8].
In Korea, ATRs in hospitals have been voluntarily reported to 
the Korean Hemovigilance System, whereas notifications of any 
ATR causing death, disability, hospitalization, or viral infection 
are mandatorily reported by the hospitals to the Korean Centers 
for Disease Control (KCDC). Initially, the KCDC took the lead in 
investigating ATRs; the division of Human Blood Safety Surveil-
lance of the KCDC has monitored ATRs using a recipient trace 
back system since 2006. However, the reported individual 
cases have not been fully reviewed yet. Therefore, the purpose 
of this study was to analyze the nationwide cases of ATR re-
ported from 2006 to 2014inan effort to improve the currently 
used  Korean Hemovigilance System.
METHODS
When suspected ATRs, including transfusion-transmitted infec-
tions (TTIs), are reported from medical institutions to commu-
nity health centers, the centers forward the information to the 
division of Human Blood Safety Surveillance of the KCDC. 
These cases are further investigated by a system called the ‘re-
cipient-triggered trace back system’. Briefly, the division of Hu-
man Blood Safety Surveillance investigates the reported cases 
by: (i) collecting information about a recipient from the hospital; 
(ii) inquiring about the blood donation history of the donors by 
searching the Blood Information Sharing System at the KRC 
Blood Services; (iii) reviewing the medical records of donors and 
recipients with the aid of the Health Insurance Review & As-
sessment Service (HIRAS); (iv) repeat testing with archived 
blood samples of the corresponding blood donation; and (v) vis-
iting blood donors for follow-up tests (Fig. 1). 
The recipient-triggered trace back system was applied in 
cases of suspected ATR that were either detected following 
transfusion during the hospital treatment course or were 
brought up by outpatients themselves who had received trans-
fusions in the past. Data collected by the trace back system 
from 2006 to 2014 were retrospectively reviewed and reas-
sessed according to the following categories: (i) related to trans-
fusion, (ii) probably related to transfusion, (iii) probably not re-
lated to transfusion, (iv) not related to transfusion, (v) unable to 
investigate, and (vi) under investigation. TTIs due to viruses 
were determined by serological tests for hepatitis B surface 
(HBs) antigen, HBs antibody, hepatitis B core (HBc) antibody, 
hepatitis C virus (HCV) antibody, HIV-1/2 antibody, human T cell 
leukemia virus (HTLV)-1 antibody, ALT, or a nucleic acid amplifi-
Fig. 1. Flowchart of trace back system for the report and investigation of transfusion-related adverse reactions in Korean Hemovigilance 
System.
Abbreviation: KCDC, Korean Centers for Disease Control.
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cation test (NAT) for hepatitis B virus (HBV), HCV, and HIV. 
When malarial infection was suspected, malarial antibody test 
and PCR assay were performed on the stored samples obtained 
from donors. Bacterial TTI was demonstrated by paired blood 
cultures of patients and blood components. In addition to TTIs, 
transfusion-related acute lung injury (TRALI), acute hemolytic 
transfusion reaction (AHR), and the other adverse conditions 
were also investigated.
RESULTS
1.  Suspected adverse reaction cases by recipient-triggered 
trace back system in Korea, 2006-2014
Of 199 reported cases, 12 (6.0%) could be confirmed as re-
lated to transfusion (Table 1 and Fig. 2). A half (49.2%) of the 
reported cases were categorized as unrelated to transfusion, 12 
(6.0%) as probably not related to transfusion, 61 (30.7%) as 
unable to investigate, and 15 (7.5%) as under investigation. 
Altogether, 199 serious adverse reactions were reported during 
the nine-year period from 2006 to 2014. HCV infection (135, 
67.8%) was reported most frequently, followed by HBV infection 
(27, 13.6%), HIV infection (13, 6.5%), syphilis (9, 4.5%), malar-
ial infection (4, 2.0%), and other bacterial infections (3, 1.5%)
(Table 2).The annual reported numbers were as follows: 53 
cases in 2006, 29 cases in 2007, 18 cases in 2008, 27 cases in 
2009, 19 cases in 2010, 11 cases in 2011, 17 cases in 2012, 
14 cases in 2013, and 11 cases in 2014. 
2.  Review of the 13 cases confirmed as ‘related to 
transfusion’
Thirteen of 199 reported cases were confirmed as ‘related to 
transfusion’ by the trace back system (Table 3). Thirteen con-
firmed cases were composed of nine cases of TTI, three cases 
of TRALI, and one case of AHR (Table 4). The TTI cases in-
cluded three cases of HCV infection, three cases of malarial in-
fection, one case of HBV infection, and two cases of Staphylo-
coccus aureus sepsis.
DISCUSSION
The Joint United Kingdom Blood Transfusion Service Profes-
sional Advisory Committee has defined the “Trace Back” system 
as an investigation performed by the Blood Establishment when 
they receive a report that a patient has been identified with a 
TTI following the transfusion of blood components [9].This sys-
tem was applied with modification to monitor severe ATRs in the 
division of Human Blood Safety Surveillance since 2006. Ini-
tially, this system mainly aimed at reducing TTIs, which have 
been problematic in Korea. Moreover, the Korean government 
encouraged reporting suspicious cases of TTI with a compensa-
tion fee paid when the cases were confirmed as ‘category 1, re-
Table 1. Classification of the suspected adverse reaction cases investigated by the trace back system in Korea, 2006-2014
Classification
N of annual reported case
Total (%)
2006 2007 2008 2009 2010 2011 2012 2013 2014
Related to transfusion 4 2 1 3 - 1 - 1 - 12 (6.0)
Probably related to transfusion - - - - - - - 1 - 1 (0.5)
Probably not related to transfusion - - - - - 1 7 3 1 12 (6.0)
Not related to transfusion 32 16 10 15 8 3 9 3 2 98 (49.2)
Unable to investigate 17 11 7 9 11 6 - - - 61 (30.7)
Under investigation - - - - - - 1 6 8 15 (7.5)
Subtotal 53 29 18 27 19 11 17 14 11 199
Fig. 2. Annual reported cases of suspected adverse reactions by 
the trace back system in Korea, 2006-2014.
Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HTLV, human 
T cell leukemia virus.
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lated to transfusion’. This might be helpful to the development 
of the recipient trace back system, by detecting TTIs even in 
patients who were transfused over five years ago (Table 4).The 
gap between the transfusion year and report year could be ex-
plained by the claims of the recipients themselves. We found 
that the number of suspected cases (53 cases) encountered in 
the first year was 2-fold higher than that encountered in the 
other years, which might be due to the accumulation of data 
before the investigation. The suspected cases have been de-
creasing annually, and cases confirmed as TTI by HBV, HCV, 
and HIV has not been reported since the introduction of NATs. 
The current study revealed only one case of HBV infection af-
ter transfusion in 1999. The donor was negative for HBs antigen 
in a donor screening test but was positive for HBs antigen after 
blood donation. This might be due to a relatively low analytical 
performance of the assay that could not overcome the window 
period of the donor’s HBV infection at that time. In Korea, the 
residual risk for HBV was reduced from 2.18 patients to 1.47 
patients per 0.1 million donors, after implementation of a che-
miluminescence immunoassay (CLIA) (Abbott Laboratories, Di-
agnostic Division, Abbott Park, IL, USA) for HBs antigen [10]. 
However, the residual risk for HBV per million donations could 
differ from the prevalence in countries in which NATs were per-
formed for donor screening: 2.8-3.6 in the United States, 1.4 in 
Britain, and 91.9 in southern Pakistan [11-13]. 
HCV infection, accounting for 76.7% (135/176), was the most 
frequently reported viral TTI in this study. This frequency is 
higher than that determined by the 11-yr German hemovigi-
lance system (58.7%, 1,699/2,894) [6]. Although the frequency 
Table 2. Annual reported cases of suspected adverse reactions investigated by the recipient-triggered trace back in Korea, 2006-2014
Category
N of annual reported cases
Total (%)
2006 2007 2008 2009 2010 2011 2012 2013 2014
HCV infection 42 25 10 15 13 8 11 6 5 135 (67.8)
HBV infection 5 0 2 2 3 2 4 6 3 27 (13.6)
HIV infection 4 1 2 3 1 0 1 0 1 13 (6.5)
Syphilis infection 1 1 2 3 0 0 1 0 1 9 (4.5)
Malarial infection* 1 2 1 0 0 0 0 0 0 4 (2.0)
Bacterial infection 0 0 0 1 0 1 0 1 0 3 (1.5)
HTLV infection 0 0 0 0 1 0 0 0 0 1 (0.5)
Scrub typhus infection 0 0 0 0 0 0 0 0 1 1 (0.5)
TRALI 0 0 0 1 1 0 0 1 0 3 (1.5)
AHR 0 0 0 1 0 0 0 0 0 1 (0.5)
Seizure 0 0 1 0 0 0 0 0 0 1 (0.5)
ARDS 0 0 0 1 0 0 0 0 0 1 (0.5)
Subtotal 53 29 18 27 19 11 17 14 11 199 (100.0)
*Three cases of malaria were reported each year from 2006 to 2008 by Kim et al. [2].
Abbreviations: AHR, acute hemolytic transfusion reaction; ARDS, acute respiratory distress syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; HTLV, 
human T cell leukemia virus; TRALI, transfusion-related acute lung injury.
Table 3. Frequency of reported and confirmed transfusion-related 
adverse reactions (2006-2014)
Adverse reactions
Total number of 
reported cases
Total number of 
confirmed cases
HCV infection 135 3
HBV infection 27 1
HIV infection 13 0
Syphilis infection 9 0
Malarial infection 4 3
Bacterial infection 3 2
HTLV infection 1 0
Scrub typhus infection 1 0
TRALI 3 3
AHR 1 1
Seizure 1 0
ARDS 1 0
Total 199 13
Abbreviations: AHR, acute hemolytic transfusion reaction; ARDS, acute 
respiratory distress syndrome; HBV, hepatitis B virus; HCV, hepatitis C virus; 
HTLV, human T cell leukemia virus; TRALI, transfusion-related acute lung 
injury.
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of reported cases was high, the number of reports has markedly 
decreased after the introduction of strict donor selection with 
NAT, resulting in a minimized infectious window of 3.4 days af-
ter June 2012. Kim et al. [10] reported that the residual risks for 
HCV in Korea have declined 36.6-fold, from 1 in 81 thousand to 
1 in 3 million, after the introduction of the NAT for HCV RNA. 
We found three cases of transfusion-related HCV infection, but 
all of them were transfused based on enzyme immunoassay 
(EIA) screening with a 58.3-day infectious window period before 
the introduction of the NAT. Considering that the most common 
cases reported as suspiciously transfusion related were HCV in-
fections, the NAT might be helpful for promoting safety in trans-
fusion. 
Since the re-emergence of malaria in 1993, Plasmodium 
vivax has become endemic in Korea and is associated with mili-
tary service along the demilitarized zone (DMZ) [14]. Seo et al. 
[15] reported that 60% of soldiers who served in the DMZ and 
were diagnosed with malaria in 1997 had donated their blood 
before diagnosis. In Korea, donor deferral criteria for cellular 
components (red blood cell and platelet) have been applied 
with restriction for periods of 12 or 36 months after domestic 
travel to, or residence in, malaria risk areas [16]. However, the 
current study found that three transfusion-mediated malaria 
cases occurred outside of malaria risk areas. Previous reports in 
the USA and UK supported that transfusion-transmitted malaria 
might be unpreventable solely by strict adherence to donor ex-
clusion guidelines [17]. The World Health Organization recom-
mends that all blood donations should be screened for malaria 
where “appropriate and possible”, and that there should be 
quality-assured testing for TTIs [18]. However, these recom-
mendations have significant resource implications. Inspection of 
malarial antigens or DNA in blood donations from malaria risk 
areas may be an additional solution for preventing transfusion-
transmitted malaria.
It is noteworthy that this is the first Korean report of transfu-
sion-transmitted bacterial sepsis caused by S. aureus described 
in an English-language journal, although there was a transfusion 
accident that 10 patients were dead in 1974 because of con-
taminated Serratia marcescens in glass blood bank bottles [19].
Two cases were observed in patients who suffered from hema-
tological malignancy and depended on repeated platelet trans-
fusion. S. aureus was found in blood cultures of both recipients 
and in the platelet component. A definite route of contamination 
could not be determined, but the same characteristic, methicil-
lin susceptibility, was demonstrated in S. aureus in both sam-
ples by an antimicrobial susceptibility test and molecular epide-
miological tests, and bacterial TTIs were confirmed. Recently, 
the US Food and Drug Administration (FDA) announced that 
bacterial transmission during transfusion was the fourth most 
common cause of fatal transfusion-associated reactions in the 
United States [20]. Little is known about bacterial TTIs in Korea, 
whereas sepsis cases associated with platelet transfusion were 
Table 4. Proven cases with adverse transfusion reaction investigated by the trace back system in Korea, 2006-2014
Patient 
No.
Adverse reactions Underlying disease Screened donor sample Follow-up donor sample
Screened 
N of donor
Transfusion-reported 
year
  1 HBV infection Neuroblastoma HBs Ag (-) HBs Ag (+) 356 1999-2006
  2 HCV infection HNP Anti-HCV Ab (-) Anti-HCV Ab (+), PCR (+) 55 2001-2006
  3 HCV infection Neuroblastoma N.A. Anti-HCV Ab (+), PCR (+) 126 2005-2006
  4 HCV infection Chronic cholangitis Anti-HCV Ab (-) Anti-HCV Ab (+), PCR (+) 60 1991-2007
  5 Malarial infection Rectal cancer Anti-malaria Ab (+), PCR (+) N.A. 3 2006-2007
  6 Malarial infection Tuberculosis, pancreatic cancer Anti-malaria Ab (+), PCR (+) N.A. 7 2006-2007
  7 Malarial infection Orthopediatric operation Anti-malaria Ab (+), PCR (+) N.A. 36 2008-2008
  8 Bacterial infection AML Staphylococcus aurerus (+) N.A. 1 2011-2011
  9 Bacterial infection MDS S. aurerus (+) N.A. 1 2013-2013
10 TRALI Malignant lymphoma N.A. N.A. 1 2009-2009
11 TRALI Gastric cancer N.A. N.A. 1 2009-2009
12 TRALI Acute cholangitis N.A. N.A. 1 2013-2013
13 AHR Laminectomy (B+) A+ N.A. 1 2009-2009
Abbreviations: AHR, acute hemolytic transfusion reaction; HBV, hepatitis B virus; HBs, hepatitis B surface; Ag, antigen; Ab, antibody; HCV, hepatitis C virus; 
HNP, herniated nucleus pulposus; N.A., not analyzed; TRALI, transfusion-related acute lung injury.
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reported in 1/25,000 transfusions in Canada and the United 
States [21]. As there are increasing numbers of immunocom-
promised patients with a tremendous need for blood transfu-
sion, more attention should be paid to bacterial TTI. Prevalence 
of bacterial TTI might be underrecognized and underreported; 
thus, further efforts for creating a proper strategy in line with the 
Korean Hemovigilance System should be required, such as de-
veloping guidelines to clarify bacterial TTI cases in medical insti-
tutions or implementing proper screening tests for bacterial 
contamination of the platelet component.
In addition to TTIs, non-infectious transfusion reactions in-
cluding three cases of TRALI and one case of hemolytic transfu-
sion reaction were also investigated by this system. With respect 
to hemolytic transfusion reaction due to ABO-incompatible 
transfusion, 255 cases were reported over eight years in the UK 
by Serious Hazards of Transfusion (SHOT) and 226 cases over 
10 yr in Japan [22, 23]. However, reported cases were limited 
in the Korean Hemovigilance System; only 12 cases were re-
ported from April 2008 to November 2012. This might be the 
result of underreporting, considering that ABO-incompatible 
blood transfusion is likely to arise from human error [24]. How-
ever, systemic surveillance has not been performed owing to a 
lack of agreement within individual medical institutions for fear 
of penalties after reporting severe transfusion reactions. Only 
several cases of TRALI have been reported in Korea [25], al-
though the US FDA has documented that the leading cause of 
transfusion-related fatality is TRALI [20]. Lack of awareness 
among healthcare professionals and lack of precise definitions 
might be the main reasons for this underreporting. 
This is the first nationwide data concerning serious ATR cases 
for a recent nine-year period in Korea. Compared with data in 
the literature in the UK, USA, and Japan, many of the ATR 
cases might be still underreported, although the trace back sys-
tem in Korea is mandatory. However, we expect that this study 
could contribute to improve the current Korean Hemovigilance 
System.
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